Cellebrite DI (NASDAQ:CLBT) Given New $15.00 Price Target at DA Davidson

Cellebrite DI (NASDAQ:CLBT) had its price objective cut by DA Davidson from $22.00 to $15.00 in a report released on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other research firms have also recently commented on CLBT. Weiss Ratings upgraded Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. Needham & Company LLC decreased their target price on Cellebrite DI from $15.00 to $12.50 and set a “buy” rating for the company in a research report on Friday. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $16.70.

Cellebrite DI Price Performance

NASDAQ CLBT opened at $11.14 on Friday. The firm’s fifty day moving average price is $14.47 and its 200 day moving average price is $14.03. The company has a market capitalization of $2.78 billion, a price-to-earnings ratio of 50.64, a price-to-earnings-growth ratio of 1.34 and a beta of 1.18. Cellebrite DI has a 12 month low of $9.58 and a 12 month high of $19.98.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings results on Thursday, August 13th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.06 by $0.05. Cellebrite DI had a net margin of 11.43% and a return on equity of 16.04%. The firm had revenue of $131.14 million for the quarter, compared to analyst estimates of $131.50 million. As a group, sell-side analysts forecast that Cellebrite DI will post 0.41 earnings per share for the current year.

Insider Buying and Selling at Cellebrite DI

In other news, CEO Thomas E. Hogan sold 139,713 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $15.39, for a total transaction of $2,150,183.07. Following the completion of the sale, the chief executive officer owned 790,548 shares in the company, valued at approximately $12,166,533.72. This represents a 15.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO David Barter sold 41,734 shares of the business’s stock in a transaction dated Wednesday, July 8th. The shares were sold at an average price of $16.38, for a total value of $683,602.92. Following the completion of the transaction, the chief financial officer owned 334,219 shares in the company, valued at $5,474,507.22. This trade represents a 11.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 297,934 shares of company stock worth $4,631,972. 5.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Cellebrite DI

Several large investors have recently modified their holdings of the stock. Towarzystwo Funduszy Inwestycyjnych PZU SA grew its position in Cellebrite DI by 81.0% in the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock valued at $34,000 after buying an additional 850 shares during the last quarter. CWM LLC increased its stake in shares of Cellebrite DI by 57.0% during the fourth quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $44,000 after acquiring an additional 889 shares during the period. SkyView Investment Advisors LLC increased its stake in shares of Cellebrite DI by 2.6% during the second quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company’s stock worth $597,000 after acquiring an additional 970 shares during the period. Alamea Verwaltungs GmbH raised its holdings in Cellebrite DI by 4.3% during the fourth quarter. Alamea Verwaltungs GmbH now owns 24,648 shares of the company’s stock worth $444,000 after purchasing an additional 1,018 shares in the last quarter. Finally, Pacer Advisors Inc. raised its holdings in Cellebrite DI by 45.1% during the fourth quarter. Pacer Advisors Inc. now owns 3,981 shares of the company’s stock worth $72,000 after purchasing an additional 1,238 shares in the last quarter. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Cellebrite DI News Roundup

Here are the key news stories impacting Cellebrite DI this week:

• Positive Sentiment: Second-quarter adjusted EPS was $0.11, above the $0.05 consensus estimate cited by MarketBeat. Management also raised its adjusted EBITDA target, while subscription revenue continued to grow. Cellebrite second-quarter earnings report
• Positive Sentiment: Lake Street, JPMorgan, D.A. Davidson and Needham lowered their price targets but retained positive ratings: Buy or Overweight. Their revised targets range from $12.50 to $16, implying roughly 12% to 44% upside based on the provided reference price. Analyst price-target updates
• Positive Sentiment: Unusual options activity included nearly 20,000 call contracts, far above average volume, indicating speculative positioning for a potential rebound.
• Neutral Sentiment: Cellebrite completed a planned CEO transition, with Shiven Ramji succeeding Thomas E. Hogan effective August 13. The change may support a strategic reset, but investors face uncertainty during the leadership handoff. CEO succession announcement
• Negative Sentiment: The key catalyst for the selloff was lowered guidance. Third-quarter revenue is expected at $145 million-$148 million, below the $150.3 million consensus, while full-year revenue guidance of $555 million-$561 million trails the $568.1 million estimate. The company also reduced its 2026 ARR outlook. Cellebrite outlook announcement
• Negative Sentiment: Quarterly revenue of $131.14 million was slightly below the $131.87 million estimate. The earnings beat was therefore overshadowed by weaker growth indicators and the reset to management’s outlook.
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations and whether prior projections and disclosures were accurate. The investigations are allegations, not findings, but add legal and reputational risk. Cellebrite investigation notice
• Negative Sentiment: Former CEO Thomas Hogan sold 139,713 shares worth approximately $2.15 million, reducing his holdings by about 15%. Although the sale may reflect the transition or personal financial planning, its timing weighs on investor sentiment. SEC insider trading filing

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.